Alexander R. Gottschalk, MD, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Alexander R. Gottschalk, MD, PhD

Assistant Professor, Department of Radiation Oncology, UCSF

Phone: (415) 353-9807 (appts)
Box 1708, UCSF
San Francisco, CA 94143-1708

View on UCSF Profiles

Cancer Center Membership

Associate Member » Prostate Cancer

Education

University of Chicago, Chicago, IL, B.A., 1988, Chemistry
University of Chicago, Chicago, IL, Ph.D., 1994, Pathology
University of Chicago, Chicago, IL, M.D., 1996, Medicine
Kaiser Permanente Medical Center, 1996-1997, Internship Medicine
University of California, San Francisco, 1997-2001, Resident Radiation Oncology


Professional Experience

  • 2001-2008
    Assistant Professor, Department of Radiation Oncology, University of California, San Francisco
  • 2007-2008
    Interim Director, CyberKnife Radiosurgery Program, Department of Radiation Oncology, University of California, San Francisco
  • 2008-present
    Associate Professor, Department of Radiation Oncology, University of California, San Francisco
  • 2008-present
    Director, CyberKnife Radiosurgery Program, Department of Radiation Oncology, University of California, San Francisco

Honors & Awards

  • 1988-96
    NIH Medical Scientist Training Program Fellowship, University of Chicago, Chicago, IL
  • 1998-99
    NIH National Research Service Award, Department of Radiation Oncology, University of California San Francisco
  • 2000
    RSNA Research and Education Foundation Roentgen Resident/Fellow Research Award
  • 2001-02
    Clinical Investigator Research Program Recipient, University of California San Francisco
  • 2002
    Invited speaker at the Radiation Oncology Young Investigator's Symposium, Bethesda, MD,
  • 2002-03
    UCSF Prostate Cancer SPORE Developmental Research Program Award
  • 2003-05
    RSNA Research Scholar Award
  • 2003-05
    American Society of Therapeutic Radiation and Oncology Junior Faculty Award

Selected Publications

  1. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer. Radiat Oncol. 2016; 11(1):8.
    View on PubMed
  2. Investigating the clinical advantages of a robotic linac equipped with a multileaf collimator in the treatment of brain and prostate cancer patients. J Appl Clin Med Phys. 2015; 16(5):5502.
    View on PubMed
  3. Intraoperative Radiotherapy in the Management of Locally Recurrent Extremity Soft Tissue Sarcoma. Sarcoma. 2015; 2015:913565.
    View on PubMed
  4. Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer. Brachytherapy. 2015 Jul 18.
    View on PubMed
  5. Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2015 Sep-Oct; 5(5):e465-72.
    View on PubMed
  6. Comparison between target margins derived from 4DCT scans and real-time tumor motion tracking: Insights from lung tumor patients treated with robotic radiosurgery. Med Phys. 2015 Mar; 42(3):1280.
    View on PubMed
  7. ACR appropriateness Criteria® Postradical prostatectomy irradiation in prostate cancer. Oncology (Williston Park). 2014 Dec; 28(12):1125-30, 1132-6.
    View on PubMed
  8. Analysis of dose distribution and risk of pneumonitis in stereotactic body radiation therapy for centrally located lung tumors: a comparison of robotic radiosurgery, helical tomotherapy and volumetric modulated arc therapy. Technol Cancer Res Treat. 2015 Feb; 14(1):49-60.
    View on PubMed
  9. Pre-plan parameters predict post-implant D90 = 140 Gy for (125)I permanent prostate implants. J Contemp Brachytherapy. 2014 Jun; 6(2):143-53.
    View on PubMed
  10. ACR Appropriateness Criteria® Definitive External-Beam Irradiation in stage T1 and T2 prostate cancer. Am J Clin Oncol. 2014 Jun; 37(3):278-88.
    View on PubMed
  11. Response to Drs Rogers, Hayes, and Demanes. Brachytherapy. 2014 Sep-Oct; 13(5):523-5.
    View on PubMed
  12. Commentary on "Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus." Kalakota K, Liauw SL, Department of Radiation Oncology, Northwestern Memorial Hospital, Chicago, IL.: Urology 2013;81(6):1196-201. doi: 10.1016/j.urology.2013.01.047. [Epub 2013 Mar 26]. Urol Oncol. 2014 Apr; 32(3):374.
    View on PubMed
  13. Commentary on "Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer." Gray PJ, Paly JJ, Yeap BY, Sanda MG, Sandler HM, Michalski JM, Talcott JA, Coen JJ, Hamstra DA, Shipley WU, Hahn SM, Zietman AL, Bekelman JE, Efstathiou JA. Harvard Radiation Oncology Program, Boston, MA.: Cancer 2013;119(9):1729-35. doi: 10.1002/cncr.27956. [Epub 2013 Feb 22]. Urol Oncol. 2014 Apr; 32(3):373-4.
    View on PubMed
  14. Commentary on "A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma." Siva S, Pham D, Gill S, Corcoran NM, Foroudi F. Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Victoria, Australia.: BJU Int 2012;110(11 Pt B):E737-43. doi: 10.1111/j.1464-410X.2012.11550.x. [Epub 2012 Oct 29]. Urol Oncol. 2014 Apr; 32(3):374-5.
    View on PubMed
  15. Endoscopic gold fiducial marker placement into the bladder wall to optimize radiotherapy targeting for bladder-preserving management of muscle-invasive bladder cancer: feasibility and initial outcomes. PLoS One. 2014; 9(3):e89754.
    View on PubMed
  16. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. Radiat Oncol. 2014; 9:42.
    View on PubMed
  17. Commentary on "secondary cancers after intensity-modulated radiotherapy, brachytherapy, and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention." Zelefsky MJ, Pei X, Teslova T, Kuk D, Magsanoc JM, Kollmeier M, Cox B, Zhang Z. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.: BJU Int 2012;110:1696-701. doi: 10.1111/j.1464-410X.2012.11385.x. [Epub 2012 Aug 13]. Urol Oncol. 2014 Feb; 32(2):209.
    View on PubMed
  18. ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. Brachytherapy. 2014 Jan-Feb; 13(1):27-31.
    View on PubMed
  19. Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: implications for focal salvage brachytherapy. Radiother Oncol. 2013 Nov; 109(2):246-50.
    View on PubMed
  20. Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife. J Appl Clin Med Phys. 2013; 14(5):162-72.
    View on PubMed

Go to UCSF Profiles, powered by CTSI